Lorlatinib and Selegiline

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with lorlatinib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2B6. The proposed mechanism, based on in vitro data, is increased clearance due to lorlatinib-mediated induction of CYP450 2B6. MANAGEMENT: Caution is recommended if lorlatinib is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when lorlatinib is prescribed in combination with drugs that are CYP450 2B6 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever lorlatinib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2B6-inducing activity may also be considered. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

MONITOR: Coadministration with lorlatinib may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 2B6. The proposed mechanism, based on in vitro data, is increased clearance due to lorlatinib-mediated induction of CYP450 2B6.

MANAGEMENT: Caution is recommended if lorlatinib is used concomitantly with drugs that are substrates of CYP450 2B6, particularly those with a narrow therapeutic range. The potential for diminished therapeutic effects should be considered when lorlatinib is prescribed in combination with drugs that are CYP450 2B6 substrates. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever lorlatinib is added to or withdrawn from therapy with these drugs. An alternative agent with no or minimal CYP450 2B6-inducing activity may also be considered.

Lorlatinib

Generic Name: lorlatinib

Brand name: Lorbrena

Synonyms: n.a.

What is Lorlatinib?

Selegiline

Generic Name: selegiline

Brand name: Eldepryl, Zelapar, Emsam

Synonyms: n.a.

What is Selegiline?